Association of TOP2A and ADH1B with Lipid Levels and Prognosis in Patients with Lung Adenocarcinoma and Squamous Cell Carcinoma

Overview

Journal Clin Respir J

Specialty Pulmonary Medicine

Date 2023 Nov 20

PMID 37985446

Authors

Dongdong Yin

Yinci Zhang

Hui Li

Longqiang Cheng

Affiliations

Soon will be listed here.

Abstract

Background: Although lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) have different pathological and clinical features, they may share common driver genes. It was found that lipid levels can be used for early diagnosis of NSCLC; however, the relationship between driver genes and genes regulating lipid metabolism and their relationship with patient prognosis needs further investigation.

Methods: Genes whose expression was up- or down-regulated in both LUAD and LUSC were identified using the GEO database. Online tools like GEPIA 2, PrognoScan, UALCAN, and TIMER2.0 were used to investigate the association of these gene expressions with the patient's prognosis and lipid regulatory genes. The association between clinical lipid levels and the risk of LUAD and LUSC was analyzed by using a multiple logistic regression model.

Results: Topoisomerase II alpha (TOP2A) and alcohol dehydrogenase 1B (ADH1B) were identified as the only genes up- and down-regulated in both LUAD and LUSC. TOP2A and ADH1B expression levels significantly correlated with the patient's gender, age, individual cancer stage, histological subtype, nodal metastasis status, and TP53 mutation status. Additionally, only LUAD patients with higher TOP2A or lower ADH1B expressions displayed poor overall and relapse-free survival rates. Moreover, TOP2A levels exhibited a negative correlation with adipose triglyceride lipase (ATGL) and ATP-binding cassette transporter A1 (ABCA1) in both LUAD and LUSC. However, ADH1B showed inverse associations with the above-mentioned genes when compared to TOP2A expressions in both LUAD and LUSC. Furthermore, elevated triglyceride (OR = 1.59; 95% CI = 1.01 to 2.49; P < 0.05) and total cholesterol (OR = 2.45; 95% CI = 1.08 to 5.57; P < 0.05) levels might increase the risk of LUAD.

Conclusions: TOP2A and ADH1B can be used as diagnostic markers for LUAD and LUSC, but only as independent prognostic factors for LUAD, and may be involved in lipid metabolism in LUAD patients but not in LUSC. Thus, combining genetic diagnostics with lipid panel tests might be an effective method for an early diagnosis and improved prognosis of LUAD.

Citing Articles

Identification and Evaluation of Hub Long Non-Coding RNAs and mRNAs in PM2.5-Induced Lung Cell Injury.

Sui J, Zhang Y, Zhang L, Xia H Int J Mol Sci. 2025; 26(3).

PMID: 39940682 PMC: 11816485. DOI: 10.3390/ijms26030911.

Exploration of telomere-related biomarkers for lung adenocarcinoma and targeted drug prediction.

Zhao J, Ye L, Yan W, Huang W, Wang G Discov Oncol. 2025; 16(1):148.

PMID: 39928198 PMC: 11811357. DOI: 10.1007/s12672-025-01847-2.

Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.

Yin D, Zhang Y, Li H, Cheng L Clin Respir J. 2023; 17(12):1301-1315.

PMID: 37985446 PMC: 10730466. DOI: 10.1111/crj.13717.

References

Gao Y, Zhao H, Ren M, Chen Q, Li J, Li Z . TOP2A Promotes Tumorigenesis of High-grade Serous Ovarian Cancer by Regulating the TGF-β/Smad Pathway. J Cancer. 2020; 11(14):4181-4192. PMC: 7196274. DOI: 10.7150/jca.42736. View

Jiang L, Fang X, Wang H, Li D, Wang X . Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells. Front Immunol. 2019; 9:2927. PMC: 6302125. DOI: 10.3389/fimmu.2018.02927. View

Wang J, Xiao Q, Wang L, Wang Y, Wang D, Ding H . Role of in Cardiovascular Disease. J Pers Med. 2022; 12(6). PMC: 9225161. DOI: 10.3390/jpm12061010. View

Yin D, Zhang Y, Li H, Cheng L . Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma. Clin Respir J. 2023; 17(12):1301-1315. PMC: 10730466. DOI: 10.1111/crj.13717. View

Wang G, Qiu M, Xing X, Zhou J, Yao H, Li M . Lung cancer scRNA-seq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis. Sci Transl Med. 2022; 14(630):eabk2756. DOI: 10.1126/scitranslmed.abk2756. View

Patel R, Santoro A, Hofer P, Tan D, Oberer M, Nelson A . ATGL is a biosynthetic enzyme for fatty acid esters of hydroxy fatty acids. Nature. 2022; 606(7916):968-975. PMC: 9242854. DOI: 10.1038/s41586-022-04787-x. View

Li R, Liu B, Liu Y, Liu Y, He Y, Wang D . Elevated serum lipid level can serve as early signal for metastasis for Non-Small Cell Lung Cancer patients: A retrospective nested case-control study. J Cancer. 2020; 11(23):7023-7031. PMC: 7592011. DOI: 10.7150/jca.48322. View

Gong K, Zhou H, Liu H, Xie T, Luo Y, Guo H . Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis. Technol Cancer Res Treat. 2021; 20:15330338211060202. PMC: 8649439. DOI: 10.1177/15330338211060202. View

Liu L, Liu A, Tewey K, Whang-Peng J, Knutsen T, Huebner K . Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A. 1988; 85(19):7177-81. PMC: 282147. DOI: 10.1073/pnas.85.19.7177. View

10.

Real J, Ascaso J . Lipid metabolism and classification of hyperlipaemias. Clin Investig Arterioscler. 2021; 33 Suppl 1:3-9. DOI: 10.1016/j.arteri.2020.12.008. View

11.

Zhang Y, Liu X, Li A, Tang X . A pan-cancer analysis on the carcinogenic effect of human adenomatous polyposis coli. PLoS One. 2022; 17(3):e0265655. PMC: 8932560. DOI: 10.1371/journal.pone.0265655. View

12.

Matejcic M, Gunter M, Ferrari P . Alcohol metabolism and oesophageal cancer: a systematic review of the evidence. Carcinogenesis. 2017; 38(9):859-872. DOI: 10.1093/carcin/bgx067. View

13.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

14.

Shih S, Huang Y, Yang H . A multiple mediator analysis approach to quantify the effects of the ADH1B and ALDH2 genes on hepatocellular carcinoma risk. Genet Epidemiol. 2018; 42(4):394-404. PMC: 5980724. DOI: 10.1002/gepi.22120. View

15.

Cochran B, Ong K, Manandhar B, Rye K . APOA1: a Protein with Multiple Therapeutic Functions. Curr Atheroscler Rep. 2021; 23(3):11. DOI: 10.1007/s11883-021-00906-7. View

16.

Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G . The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015; 10(7):990-1003. DOI: 10.1097/JTO.0000000000000559. View

17.

Brooks P, Zakhari S . Acetaldehyde and the genome: beyond nuclear DNA adducts and carcinogenesis. Environ Mol Mutagen. 2013; 55(2):77-91. DOI: 10.1002/em.21824. View

18.

Xu Z, Peng B, Kang F, Zhang W, Xiao M, Li J . The Roles of Drug Metabolism-Related ADH1B in Immune Regulation and Therapeutic Response of Ovarian Cancer. Front Cell Dev Biol. 2022; 10:877254. PMC: 9218672. DOI: 10.3389/fcell.2022.877254. View

19.

Lambert G, Sjouke B, Choque B, Kastelein J, Hovingh G . The PCSK9 decade. J Lipid Res. 2012; 53(12):2515-24. PMC: 3494258. DOI: 10.1194/jlr.R026658. View

20.

Whitfield A, Barrett P, Bockxmeer F, Burnett J . Lipid disorders and mutations in the APOB gene. Clin Chem. 2004; 50(10):1725-32. DOI: 10.1373/clinchem.2004.038026. View